MARK VELLEK
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LAS VEGAS, NV NPI 1063409688
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NV PFIZER INC. All categories
General Payments — all program years on this page
$4,059.86
- Category: General Payments
- Program years: PY2018–2024
- Record count: 229
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,114.70 across 61 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,106.58 | 60 |
| Education | $8.12 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $177.67 | 11 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $141.88 | 7 |
| ABBVIE INC. | $81.30 | 4 |
| Acerta Pharma LLC | $79.73 | 4 |
| Tempus AI, Inc | $62.98 | 3 |
| Merck Sharp & Dohme Corporation | $61.93 | 3 |
| Lilly USA, LLC | $51.24 | 3 |
| Janssen Biotech, Inc. | $46.33 | 3 |
| GENZYME CORPORATION | $42.32 | 2 |
| Celgene Corporation | $32.28 | 2 |
| Daiichi Sankyo Inc. | $29.57 | 1 |
| Siemens Medical Solutions USA, Inc. | $29.26 | 1 |
| E.R. Squibb & Sons, L.L.C. | $29.12 | 2 |
| Stemline Therapeutics Inc. | $28.86 | 2 |
| Incyte Corporation | $28.27 | 1 |
| Sandoz Inc. | $23.79 | 1 |
| Coherus Biosciences Inc. | $22.39 | 1 |
| Regeneron Healthcare Solutions, Inc. | $20.32 | 1 |
| Sumitomo Pharma America, Inc. | $18.50 | 1 |
| Gilead Sciences, Inc. | $17.97 | 1 |
| TerSera Therapeutics LLC | $17.66 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.59 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $15.98 | 1 |
| Rigel Pharmaceuticals, Inc. | $15.46 | 1 |
| Mirati Therapeutics, Inc. | $13.16 | 1 |
| ARRAY BIOPHARMA INC | $9.14 | 2 |
By program year
Records — PY2024 (61)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.